Five-year results of the ABSORB III trial suggest that, while target lesion failure and scaffold thrombosis have remained apparent in patients implanted with bioresorbable vascular scaffolds, the poor outcomes associated with BVS seemed to subside after three years, when the stents had completely dissolved.

The American Society of Nuclear Cardiology, together with eight other nuclear medicine and cardiology societies, have published a consensus document outlining the best practices for imaging and diagnosing cardiac amyloidosis.

Handheld POC echo has proven useful in- and outside of the emergency department, but physicians still have reservations.

With minimally invasive structural procedures crowding out their surgical counterparts, how are physicians and hospitals preparing for the new reality? 

“We anticipate that these expert multisocietal consensus recommendations on multimodality imaging in cardiac amyloidosis will standardize the diagnosis and improve the management of this highly morbid and underdiagnosed disease," wrote authors of the new guidelines published in the Journal of Nuclear Cardiology.

Multiple nuclear medicine and cardiology groups are working to oppose potential cuts to myocardial PET scans that were made possible by the CMS 2020 Medicare Physician Fee Schedule (MPFS) proposed rule, according to a joint statement.

Orchestra BioMed, Inc., on Sept. 4 announced it received CE mark approval for its Moderato implantable pulse generation system, which delivers the company’s trademarked cardiac neuromodulation therapy to patients while simultaneously acting as a pacemaker.

When CMS released the 2020 Medicare Physician Fee Schedule (MPFS) proposed rule, it included revisions that could lead to technical component payment reductions of up to 80% for certain services related to myocardial PET scans.